Bexagliflozin vs Canagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Bexagliflozin · Brenzavvy
Marketed by Theracos and partners
NCT02558296 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison at week 24 was statistically significant in favor of bexagliflozin. HbA1c is an approvable primary endpoint in type 2 diabetes, so the design and the result support strong evidence.
Next expected readout: March 2029 · NCT07547878 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) (met)
Result source: NCT02769481
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT01032629 · Phase 3 · completed
The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.
Next expected readout: December 2026 · NCT05427084 (registry estimate)
Reported efficacy
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)
Result source: NCT03170518
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bexagliflozin | Canagliflozin |
|---|---|---|
| HbA1c, change | -0.8% vs -0.4%−0.5 vs placeboNCT0255829623 other results
| -0.4% vs 0.4%−0.8 vs placeboNCT0317051841 other results
|
| Body weight, change (kg) | -3.0 vs -0.4−2.6 vs placeboNCT0255829614 other results
| -2.9 vs -0.8−2.1 vs placeboNCT006422788 other results
|
| HbA1c below 7% | —Not reported | 42.8% vs 43%vs Metformin XRNCT018093276 other results
|
| Fasting plasma glucose, change | -2.5 vs -1.2−1.3 vs placeboNCT0325978910 other results
| -0.6 vs 0.2−0.7 vs placeboNCT0103262934 other results
|
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT04304261 |
HbA1c, change
- Bexagliflozin
- -0.8% vs -0.4%−0.5 vs placeboNCT02558296
23 other results
- -1.1% vs -0.6% NCT03259789
- -0.5% vs -0.1% NCT02715258
- -0.6% vs -0.3% NCT02836873
- -0.7% vs -0.8% NCT03115112
- -0.7% vs -0.7% NCT02769481
- -1.1% vs -0.6% NCT03259789
- -0.6% vs -0.4% NCT02836873
- -0.6% vs -0.2% NCT02836873
- -1% vs -0.5% NCT03259789
- -1.0% vs -0.3% NCT03259789
- -0.7% vs -0.2% NCT03259789
- -0.6% vs 0.2% NCT02390050
- -0.4% vs 0.2% NCT02390050
- -0.3% vs 0.2% NCT02390050
- -0.6% vs 0.2% NCT02390050
- -0.4% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- -0.4% vs 0.2% NCT02390050
- -0.4% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- -0.3% vs 0.2% NCT02390050
- -0.3% vs 0.1% NCT02390050
- -0.1% vs 0% NCT02390050
- Canagliflozin
- -0.4% vs 0.4%−0.8 vs placeboNCT03170518
41 other results
- -0.7% vs -0.0% NCT01106651
- -0.4% vs -0.0% NCT01064414
- -1.0% vs -0.3% NCT01106690
- -1.1% vs -0.1% NCT01106625
- -1.0% vs 0.1% NCT01081834
- -1.1% vs -0.5% NCT01381900
- -0.6% vs -0.0% NCT01106651
- -0.3% vs -0.0% NCT01064414
- -0.9% vs -0.3% NCT01106690
- -0.8% vs -0.1% NCT01106625
- -0.8% vs 0.1% NCT01081834
- -1.0% vs -0.5% NCT01381900
- -1.0% vs -0.1% NCT02354235
- -1.4% vs -1.3% NCT01809327
- -0.9% vs -0.8% NCT01106677
- -0.9% vs -0.8% NCT00968812
- -1.0% vs -0.7% NCT01137812
- -1.4% vs -1.3% NCT01809327
- -0.8% vs -0.8% NCT01106677
- -0.8% vs -0.8% NCT00968812
- -1.8% vs -1.3% NCT01809327
- -1.8% vs -1.3% NCT01809327
- -0.3% vs 0.0% NCT01032629
- -0.3% vs 0.0% NCT01032629
- -0.6% vs 0.1% NCT03170518
- -0.3% vs 0.7% NCT03170518
- -0.9% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.7% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.9% vs -0.2% NCT00642278
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.2% NCT00642278
- -0.7% vs -0.2% NCT00642278
- -0.6% vs -0.0% NCT01340664
- -0.5% vs -0.0% NCT01340664
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.0% NCT02025907
- -1.0% vs 0.1% NCT02220920
- -0.9% vs -1.1% NCT02622113
- 7.8% vs 8.3% NCT02964585
Body weight, change (kg)
- Bexagliflozin
- -3.0 vs -0.4−2.6 vs placeboNCT02558296
14 other results
- -3.6 vs -1.1 NCT03259789
- -1.9 vs -1.1 NCT02715258
- -2.3 vs -0.6 NCT02836873
- -3.4 vs -0.8 NCT03115112
- -3.7 vs 0.6 NCT02769481
- -1.9 vs -0.1 NCT02390050
- -1.5 vs 0.0 NCT02390050
- -1.0 vs 0 NCT02390050
- -1.7 vs -0.1 NCT02390050
- -1.4 vs 0.0 NCT02390050
- -0.8 vs 0 NCT02390050
- -1.6 vs -0.1 NCT02390050
- -1 vs 0.0 NCT02390050
- -0.7 vs 0 NCT02390050
- Canagliflozin
- -2.9 vs -0.8−2.1 vs placeboNCT00642278
8 other results
- -1.5 vs 0.1 NCT01939496
- -2.3 vs -0.8 NCT00642278
- -1.0 vs 0.1 NCT01939496
- -2.9 vs -0.8 NCT00642278
- -2.3 vs -0.8 NCT00642278
- -2.0 vs -0.8 NCT00642278
- -3.5 vs -1.9 NCT02324842
- -6 vs -1.9 NCT02324842
HbA1c below 7%
- Bexagliflozin
- —Not reported
- Canagliflozin
- 42.8% vs 43%vs Metformin XRNCT01809327
6 other results
- 38.8% vs 43% NCT01809327
- 56.8% vs 43% NCT01809327
- 49.6% vs 43% NCT01809327
- 57.1% vs 31.5% NCT01340664
- 47.8% vs 31.5% NCT01340664
- 32.3% vs 12.2% NCT02025907
Fasting plasma glucose, change
- Bexagliflozin
- -2.5 vs -1.2−1.3 vs placeboNCT03259789
10 other results
- -1.8 vs -1.4 NCT03115112
- -1.2 vs -0.1 NCT02390050
- -1.0 vs 0.1 NCT02390050
- -1.1 vs -0.1 NCT02390050
- -1.2 vs -0.1 NCT02390050
- -1.1 vs 0.1 NCT02390050
- -1.0 vs -0.1 NCT02390050
- -1.0 vs -0.1 NCT02390050
- -0.8 vs 0.1 NCT02390050
- -0.6 vs -0.1 NCT02390050
- Canagliflozin
- -0.6 vs 0.2−0.7 vs placeboNCT01032629
34 other results
- -0.4 vs 0.2 NCT01032629
- -1.1 vs 0.4 NCT01106651
- -0.7 vs 0.0 NCT01064414
- -1.8 vs 0.1 NCT01106690
- -1.7 vs 0.2 NCT01106625
- -1.9 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1 vs 0.4 NCT01106651
- -0.8 vs 0.0 NCT01064414
- -1.5 vs 0.1 NCT01106690
- -1.0 vs 0.2 NCT01106625
- -1.5 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1.9 vs 0.2 NCT02354235
- -2.1 vs -1.1 NCT01106677
- -1.9 vs -1.0 NCT01106677
- -1.7 vs -0.3 NCT01137812
- -1.5 vs -1.1 NCT01106677
- -1.4 vs -1.0 NCT01106677
- 9.7 vs 9.8 NCT02324842
- 10.0 vs 9.8 NCT02324842
- -1.4 vs 0.2 NCT00642278
- -1.3 vs -0.4 NCT01939496
- -1.4 vs 0.2 NCT00642278
- -0.0 vs -0.4 NCT01939496
- -1.3 vs 0.2 NCT00642278
- -1.5 vs 0.2 NCT00642278
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.2 NCT00642278
- -1.6 vs -0.1 NCT02025907
- -1.9 vs -0.1 NCT02220920
- -1.8 vs -1.8 NCT02622113
- 7.9 vs 8.8 NCT02964585
3-point MACE (% with event)
- Bexagliflozin
- —Not reported
- Canagliflozin
- —Not posted · NCT04304261
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Bexagliflozin: 6 of 6 rows · Canagliflozin: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bexagliflozin Rows use multiple source trials | Canagliflozin Rows use multiple source trials |
|---|---|---|
| SBP absolute change · mmHg | -5.03 vs 2.04 placebo mmHg @ 24wk20 mga,b,c NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 2 other source trials-4.23 vs -1.9 Sitagliptin mmHg @ 24wk NCT03115112 · Phase 3 -10.14 vs -7.51 placebo mmHg @ 24wk20 mg NCT02836873 · Phase 3 | -4.65 vs -0.66 Sitagliptin mmHg @ 52wk300 mgd,a,b,c NCT01106677 · Phase 3 · registry result, not featured evidence show 1 more dose-3.53 vs -0.66 Sitagliptin mmHg @ 52wk100 mg NCT01106677 · Phase 3 · registry result, not featured evidence |
| Seated SBP absolute change · mmHg | -13.48 vs -6.95 Glimepiride mmHg @ 60wke,b,f NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 0 vs 1.5 placebo mmHg @ 52wk100/300 mge,b,f NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 |
| Dropout rate | 3.9%20 mgg NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results15.5% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.8%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 11.4%20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.3% NCT03115112 · Phase 3 3.2%20 mg NCT02836873 · Phase 3 9.2%20 mg NCT02390050 · Phase 2 · registry result, not featured evidence 5.6%10 mg NCT02390050 · Phase 2 · registry result, not featured evidence 6.9%5 mg NCT02390050 · Phase 2 · registry result, not featured evidence —Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence —Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence | 6.1%300 mgh NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results7%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 33.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 29%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 0.7%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence 1.2% NCT01989754 · Phase 4 · registry result, not featured evidence 13.2% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02025907 · Phase 4 · registry result, not featured evidence 3.9% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 3.6%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 5.3%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 9.2%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 11%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 10.5%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 5.1%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 24.6%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 23.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 5.3%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 4%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 7.9%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 16.7%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.4%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 8%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 12%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 12.5%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 17.3%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 17.8%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 32.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 14%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 8.6%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 12.5%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 10.9%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 13.8%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 13.3%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination |
| Discontinued due to AEs | 0.8%20 mgg NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results1.4% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.9%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 —20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.6% NCT03115112 · Phase 3 0.6%20 mg NCT02836873 · Phase 3 —20 mg NCT02390050 · Phase 2 · registry result, not featured evidence —10 mg NCT02390050 · Phase 2 · registry result, not featured evidence —5 mg NCT02390050 · Phase 2 · registry result, not featured evidence —Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy —Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination —Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence —Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence | —300 mgh NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results—100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT02065791 · Phase 3 — NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence — NCT01989754 · Phase 4 · registry result, not featured evidence 5.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 0.9% NCT02025907 · Phase 4 · registry result, not featured evidence 1.3% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.3%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 3.4%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 1.7%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 9.7%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.1%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 4.4%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 0.9%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 1.6%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 7.5%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.1%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 3.1%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 4.7%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 3.1%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence —Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence —Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination |
| Serious AEs | 33%20 mgg NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more results11.7% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.9%20 mg NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 0.7%20 mg NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.7% NCT03115112 · Phase 3 7%20 mg NCT02836873 · Phase 3 2.6%20 mg NCT02390050 · Phase 2 · registry result, not featured evidence 4.2%10 mg NCT02390050 · Phase 2 · registry result, not featured evidence 0%5 mg NCT02390050 · Phase 2 · registry result, not featured evidence 0%Study 1: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 1: Bexagliflozin and Probene NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Study 2: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 2: Bexagliflozin and Rrifamp NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Study 3: Bexagliflozin Alone NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy 0%Study 3: Bexagliflozin and Verapam NCT03296800 · Phase 1 · registry result, not featured evidence · combination 0%Bexagliflozin Tablet Dosed in Fast NCT02820298 · Phase 1 · registry result, not featured evidence 0%Bexagliflozin Tablet Dosed in Fed NCT02820298 · Phase 1 · registry result, not featured evidence | 42.1%300 mgh NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results41.6%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.7%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.7%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.9%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 33.5%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 17.6% NCT02920918 · Phase 4 · registry result, not featured evidence 24.6% NCT01989754 · Phase 4 · registry result, not featured evidence 9.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 7% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 1.9% NCT02025907 · Phase 4 · registry result, not featured evidence 4% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.4% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 3%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 18.2%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.4%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 16.6%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 1.8%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 23.6%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.1%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 20%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 6.1%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 7.1%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 2.7%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.8%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.2%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 4.5%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 2.3%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 1%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 2.5%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 0%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 6.4%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 3.2%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 0%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.6%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 0%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination |
| Most frequent reported AEs | 20 mgg hypoglycaemia 42% (placebo 43.4%) urinary tract infection 11.3% (placebo 10.6%) upper respiratory tract infection 9.9% (placebo 9.3%) NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 16 more resultshypoglycemia 16.9% nasopharyngitis 13.6% urinary tract infection 11.7% NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20 mg nasopharyngitis 5.7% (placebo 8.2%) polydipsia 3.2% (placebo 2.5%) polyuria 3.2% (placebo 3.8%) NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3 20 mg polyuria 7.2% (placebo 2.9%) urinary tract infection 5.1% (placebo 2.9%) abdominal pain 3.6% (placebo 7.2%) NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20 mg hypoglycaemia 25.5% (placebo 25.8%) polyuria 7.6% (placebo 4.5%) nasopharyngitis 7% (placebo 8.4%) NCT02836873 · Phase 3 20 mg hypoglycemia 5.3% (placebo 1.4%) dysuria 3.9% (placebo 1.4%) nasopharyngitis 3.9% (placebo 4.2%) NCT02390050 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 5.6% (placebo 4.2%) pharyngitis 4.2% (placebo 0%) arthralgia 2.8% (placebo 0%) NCT02390050 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 6.9% (placebo 4.2%) diarrhea 2.8% (placebo 2.8%) dizziness 2.8% (placebo 1.4%) NCT02390050 · Phase 2 · registry result, not featured evidence diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 6.3% gastrointestinal sounds abnormal 6.3% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination laceration 6.3% presyncope 6.3% diarrhea 0% NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy diarrhea 0% gastrointestinal sounds abnormal 0% laceration 0% NCT03296800 · Phase 1 · registry result, not featured evidence · combination dizziness 4.2% headache 4.2% nasal congestion 4.2% NCT02820298 · Phase 1 · registry result, not featured evidence chest discomfort 4.3% dizziness 4.3% headache 4.3% NCT02820298 · Phase 1 · registry result, not featured evidence | 300 mgh hypoglycaemia 14.6% (placebo 12.1%) nasopharyngitis 14.1% (placebo 15.3%) urinary tract infection 11% (placebo 8.9%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 59 more results100 mg nasopharyngitis 15.6% (placebo 15.3%) hypoglycaemia 12.5% (placebo 12.1%) upper respiratory tract infection 10.9% (placebo 11.3%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 11.3% diarrhoea 8% upper respiratory tract infection 7.8% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 7.6% diarrhoea 6.8% upper respiratory tract infection 5.6% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 9.7% urinary tract infection 9.1% upper respiratory tract infection 7.5% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 6.8% back pain 6% urinary tract infection 5.4% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg urinary tract infection 29.4% (placebo 4.6%) urinary tract infection 29.4% (placebo 4.6%) nausea 11.8% (placebo 1.1%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg headache 11.9% (placebo 3.4%) headache 11.9% (placebo 3.4%) nasopharyngitis 11.9% (placebo 5.7%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 300 mg fatigue 3.2% diarrhoea 1.6% discomfort 1.6% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 17.6% hypotensive event 11.8% arrhythmic events 5.9% NCT02920918 · Phase 4 · registry result, not featured evidence balanoposthitis 3.2% (placebo 0.9%) NCT01989754 · Phase 4 · registry result, not featured evidence blood glucose decreased 40% (placebo 23.9%) hypoglycaemia 38.7% (placebo 32.8%) nasopharyngitis 34.7% (placebo 25.4%) NCT02622113 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 33.8% gastroenteritis 9.9% hypoglycaemia 9.9% NCT02227849 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 5.6% (placebo 5.6%) back pain 2.8% (placebo 0.9%) depression 2.8% (placebo 0%) NCT02025907 · Phase 4 · registry result, not featured evidence blood glucose decreased 26.7% (placebo 16.9%) hypoglycaemia 25.3% (placebo 21.1%) nasopharyngitis 16% (placebo 18.3%) NCT02220920 · Phase 4 · registry result, not featured evidence · combination 300 mg pollakiuria 5.4% (placebo 1.8%) nasopharyngitis 0% (placebo 0%) NCT01939496 · Phase 4 · registry result, not featured evidence 100 mg nasopharyngitis 5.3% (placebo 0%) pollakiuria 1.8% (placebo 1.8%) NCT01939496 · Phase 4 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 18.6% (placebo 16.2%) NCT02354235 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 3.8% upper respiratory tract infection 2.5% back pain 2.1% NCT01809327 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 3.8% glomerular filtration rate decreased 2.5% influenza 2.5% NCT01809327 · Phase 3 · registry result, not featured evidence diarrhoea 4.2% headache 3% influenza 3% NCT01809327 · Phase 3 · registry result, not featured evidence · combination diarrhoea 4.2% headache 3.8% influenza 3.4% NCT01809327 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 18.6% (placebo 15.2%) hypoglycaemia 15.3% (placebo 19.8%) urinary tract infection 14.8% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 9.7% (placebo 19.8%) nasopharyngitis 8.1% (placebo 15.2%) urinary tract infection 7.2% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 18.7% (placebo 15.2%) hypoglycaemia 15.4% (placebo 19.8%) urinary tract infection 13.3% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 10.4% (placebo 19.8%) nasopharyngitis 9.5% (placebo 15.2%) influenza 5.8% (placebo 7.6%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 7.5% (placebo 4%) upper respiratory tract infection 5.7% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 9% (placebo 4%) upper respiratory tract infection 3.1% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 11.2% (placebo 4.4%) nasopharyngitis 7.9% (placebo 11.1%) urinary tract infection 7.9% (placebo 5.6%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 22.5% (placebo 4.4%) urinary tract infection 13.5% (placebo 5.6%) nasopharyngitis 10.1% (placebo 11.1%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 14.4% (placebo 4.4%) arthralgia 4.4% (placebo 2.2%) bronchitis 4.4% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 20% (placebo 4.4%) arthralgia 5.6% (placebo 2.2%) bronchitis 5.6% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 9.6% (placebo 5.2%) pollakiuria 6.1% (placebo 0.9%) arthralgia 5.3% (placebo 1.7%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 13.2% (placebo 5.2%) arthralgia 7.9% (placebo 1.7%) urinary tract infection 7.9% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 8% (placebo 6.1%) back pain 7.1% (placebo 2.6%) nasopharyngitis 5.3% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 12.4% (placebo 6.1%) nasopharyngitis 9.7% (placebo 5.2%) back pain 8.8% (placebo 2.6%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 4.9% upper respiratory tract infection 4.9% urinary tract infection 3.5% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.3% upper respiratory tract infection 6.3% urinary tract infection 4.6% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg pollakiuria 5.7% urinary tract infection 4.9% nasopharyngitis 4.1% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 7.3% pollakiuria 5.7% headache 5.2% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.4% (placebo 3.2%) hypoglycaemia 5.8% (placebo 3.8%) nasopharyngitis 5.1% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 7.1% (placebo 3.2%) hypoglycaemia 7.1% (placebo 3.8%) nasopharyngitis 5.8% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 10.8% (placebo 6.4%) hypoglycaemia 7% (placebo 3.8%) urinary tract infection 5.7% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 13.4% (placebo 6.4%) hypoglycaemia 8.3% (placebo 3.8%) urinary tract infection 7.6% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 6.8% (placebo 5.2%) pain in extremity 6.8% (placebo 0%) urinary tract infection 4.5% (placebo 4.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 8.1% (placebo 5.2%) back pain 6.1% (placebo 3.1%) headache 6.1% (placebo 3.6%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 10.2% (placebo 5.2%) headache 8.6% (placebo 3.6%) back pain 7.6% (placebo 3.1%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 6.4% (placebo 4.2%) nasopharyngitis 4.3% (placebo 5.2%) pain in extremity 2.1% (placebo 0%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 7.2% (placebo 3.6%) urinary tract infection 7.2% (placebo 4.2%) nasopharyngitis 5.1% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 9.7% (placebo 3.6%) urinary tract infection 8.2% (placebo 4.2%) nasopharyngitis 7.2% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 17.5% nasopharyngitis 8.8% upper respiratory tract infection 8.8% NCT01137812 · Phase 3 · registry result, not featured evidence 300 mg daily headache 4.7% (placebo 3.1%) nausea 4.7% (placebo 0%) abdominal pain upper 3.1% (placebo 1.5%) NCT00642278 · Phase 2 · registry result, not featured evidence 100 mg daily headache 7.8% (placebo 3.1%) urinary tract infection 3.1% (placebo 6.2%) vulvovaginal mycotic infection 3.1% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence 300 mg twice daily nausea 7.8% (placebo 0%) abdominal pain upper 6.3% (placebo 1.5%) urinary tract infection 4.7% (placebo 6.2%) NCT00642278 · Phase 2 · registry result, not featured evidence 200 mg daily urinary tract infection 9.2% (placebo 6.2%) vulvovaginal mycotic infection 6.2% (placebo 0%) headache 3.1% (placebo 3.1%) NCT00642278 · Phase 2 · registry result, not featured evidence 50 mg daily nasopharyngitis 7.8% (placebo 3.1%) vulvovaginal mycotic infection 6.3% (placebo 0%) nausea 4.7% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence urinary frequency increased 86.7% dry mouth 26.7% light-headedness/dizziness 26.7% NCT02324842 · Phase na · registry result, not featured evidence nausea 53.3% dry mouth 40% constipation 33.3% NCT02324842 · Phase na · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 52 weeks versus 24 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation context differs: age eligibility differs (includes children versus adolescents and adults); baseline_threshold differs (hba1c<=11, hba1c>=6.5 versus bmi<=45).
- fAssessment timepoints differ: 52 weeks versus 60 weeks.
- gPopulation comparability has not been reviewed for 13 of these studies.
- hPopulation comparability has not been reviewed for 65 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bexagliflozin
show 6 more results
Canagliflozin
show 1 more result
show 2 more results
show 2 more results
show 33 more results
show 1 more result
+ 38 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · Canagliflozin's landscape